Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06472245
Title Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA)
Acronym ARTEMIA
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors OSE Immunotherapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST